Efficacy of E3810 for the prevention of gastric or duodenal ulcer caused by low-dose aspirin

Prevention of Recurrent Gastric or Duodenal Ulcers caused by Low-dose Aspirin with Rabeprazole (E3810) Treatment. -A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial-(Planetarium study)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221499

Enrollment

450

Registered

2011-06-29

Start date

2011-06-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric or duodenal ulcers caused by low-dose aspirin

Interventions

investigational material(s) Generic name etc : E3810(Pariet) INN of investigational material : Rabeprazole sodium Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Require long-term administration of low-dose aspirin (81 mg/day or 100 mg/day). Confirmed to have a history of gastric or duodenal ulcer.

Exclusion criteria

Exclusion criteria: Confirmed to have acute gastroduodenal mucosal lesions, gastric or duodenal ulcer, or upper gastrointestinal (esophagus, stomach, duodenum) bleeding. Confirmed to have reflux esophagitis or long segment Barrett's esophagus.

Design outcomes

Primary

Measure	Time frame
Cumulative recurrent rates of gastric or duodenal ulcers Mucosal injuries with a white coat measuring >- 3 mm in diameter will be diagnosed as ulcers	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026